Phio Pharmaceuticals Corp PHIO

NAS: PHIO | ISIN: US71880W2044   26/04/2024
0,682 USD (-3,40%)
(-3,40%)   26/04/2024

13 oktober 2023 · Thinking about buying stock in T2 Biosystems, Lucid Group, Femasys, Groupon Inc, or Phio Pharmaceuticals? · Persbericht

12 oktober 2023 · Thinking about buying stock in Phio Pharmaceuticals, Barrick Gold, Clearmind Medicine, Athersys Inc, or Wheeler Real Estate Investment Trust? · Persbericht

2 juni 2023 · Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules · Persbericht

31 mei 2023 · Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules · Persbericht

24 mei 2023 · Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute · Persbericht

18 mei 2023 · Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells · Persbericht

16 mei 2023 · Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas · Persbericht

11 mei 2023 · Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update · Persbericht

20 april 2023 · Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

18 april 2023 · Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

18 april 2023 · Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL · Persbericht

17 april 2023 · Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity · Persbericht

22 maart 2023 · Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update · Persbericht

22 februari 2023 · Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer · Persbericht

13 februari 2023 · Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements · Persbericht

10 februari 2023 · Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification · Persbericht

25 januari 2023 · Phio Pharmaceuticals Announces Reverse Stock Split · Persbericht

6 januari 2023 · Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco · Persbericht

6 januari 2023 · Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors · Persbericht

21 december 2022 · Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma · Persbericht

Mijn selecties